Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 248 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: DVT Clear all
Completed Phase 3 Interventional Results available

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

NCT02585713
View directory record Official record
Conditions
Cerebral Vein Thrombosis, Deep Vein Thrombosis, Gonadal Thrombosis, Hepatic Thrombosis, Malignant Neoplasm, Mesenteric Thrombosis, Metastatic Malignant Neoplasm, Portal Vein Thrombosis, Pulmonary Embolism, Renal Vein Thrombosis, Splenic Thrombosis, Venous Thromboembolism
Interventions
Apixaban, Dalteparin, Questionnaire Administration
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
18
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Evanston, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 23, 2026, 12:21 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial to Evaluate the Accuracy of [99mTc] ThromboView in the Detection of Deep Vein Thrombosis

NCT00123734
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
ThromboView
Drug
Lead sponsor
Agen Biomedical
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
5
States / cities
Sacramento, California • San Diego, California • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2009 · Synced Oct 23, 2026, 12:21 AM EDT
Completed No phase listed Observational

Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data

NCT05083455
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolus
Interventions
Rivaroxaban, Enoxaparin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
89,215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 23, 2026, 12:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Preliminary Clinical Usability Study for the Recovery Force DVT II Cuff

NCT03328624
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thrombosis
Interventions
Deep Vein Thrombosis (DVT) Cuff
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 23, 2026, 12:21 AM EDT
Completed Not applicable Interventional Results available

Thrombelastography Based Dosing of Enoxaparin

NCT00990236
View directory record Official record
Conditions
Thromboembolic Complications
Interventions
Enoxaparin dose adjusted Lovenox based on TEG, Enoxaparin 30 mg BID
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Portland, Oregon • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 23, 2026, 12:21 AM EDT
Completed No phase listed Observational

Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism

NCT00788736
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
2,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
2
States / cities
Burlington, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 23, 2026, 12:21 AM EDT
Terminated Phase 2 Interventional Results available

Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma

NCT00790452
View directory record Official record
Conditions
Glioblastoma
Interventions
Aspirin, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Oct 23, 2026, 12:21 AM EDT
Terminated No phase listed Observational

Prospective Assessment of the Deep Vein Thrombosis (DVT) in Hospitalized Obstetrics Patients

NCT02697123
View directory record Official record
Conditions
Venous Thrombosis, Pregnancy
Interventions
antepartum and postpartum
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 23, 2026, 12:21 AM EDT
Recruiting Phase 3 Interventional

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

NCT07213778
View directory record Official record
Conditions
Symptomatic Venous Thromboembolism (VTE)
Interventions
REGN7508, Acetylsalicylic Acid (ASA), Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
38
States / cities
La Mesa, California • Rancho Mirage, California • Riverside, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 12:21 AM EDT
Not listed Not applicable Interventional

SToP: Venous Thromboembolism Screening in the Trauma Population

NCT02978950
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis, Trauma, Multiple
Interventions
Duplex ultrasound surveillance, No ultrasound surveillance
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 23, 2026, 12:21 AM EDT
Not listed Phase 1Phase 2 Interventional

Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis

NCT04833764
View directory record Official record
Conditions
Post-thrombotic Syndrome, Deep Vein Thrombosis Leg
Interventions
Rosuvastatin
Drug
Lead sponsor
Khanh Nguyen
Federal
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 23, 2026, 12:21 AM EDT
Active, not recruiting Not applicable Interventional

TED Stocking vs. Reparel Garment After Hip Replacement

NCT07246200
View directory record Official record
Conditions
Osteoarthritis (OA) of the Hip
Interventions
Reparel Bioactive Sleeve, TED Stocking
Device
Lead sponsor
Reparel
Industry
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 23, 2026, 12:21 AM EDT
Enrolling by invitation Not applicable Interventional

DVT Evaluation Using POCUS for Diagnosis and Treatment

NCT07400510
View directory record Official record
Conditions
Deep Venous Thromboses
Interventions
STAT Venous Duplex, Routine Venous Duplex
Diagnostic Test
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 23, 2026, 12:21 AM EDT
Completed No phase listed Observational

Deep Venous Thrombus Characteristics and Venous Dynamics With Subsequent Thrombus Resolution and Post-thrombotic Syndrome

NCT04597138
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 23, 2026, 12:21 AM EDT
Completed No phase listed Observational

Association Between Genetic Variant Scores and Warfarin Effect

NCT03894878
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Intracardiac Thrombus, Pulmonary Embolism, Venous Thromboembolic Disease
Interventions
Not listed
Lead sponsor
Cipherome, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 23, 2026, 12:21 AM EDT
Completed Phase 3 Interventional Results available

Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.

NCT00056550
View directory record Official record
Conditions
Antithrombin Deficiency, Congenital
Interventions
Recombinant Human Antithrombin (rhAT)
Biological
Lead sponsor
rEVO Biologics
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
Marietta, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Oct 23, 2026, 12:21 AM EDT
Completed Phase 2 Interventional Results available

t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection

NCT03672006
View directory record Official record
Conditions
Central Venous Catheter Thrombosis, Central Venous Catheter Associated Bloodstream Infection
Interventions
alteplase (recombinant t-PA), Heparin
Biological · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 23, 2026, 12:21 AM EDT
Completed Phase 1 Interventional

Twice Daily Enoxaparin Prophylaxis in Reconstructive Surgery Patients

NCT02687204
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolus
Interventions
Twice daily enoxaparin prophylaxis, Real time dose adjustment
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 23, 2026, 12:21 AM EDT
Terminated No phase listed Observational

Permission to Collect Blood Over Time for Research

NCT00767234
View directory record Official record
Conditions
Pancreatic Cancer, Gastrointestinal Neoplasms, Colon Rectal Cancer Adenocarcinoma, Esophageal Cancer, Gall Bladder Cancer, Gastric (Stomach) Cancer, Gastrooesophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatobiliary Neoplasm, Liver Carcinoma, Gallbladder Carcinoma, Bile Duct Carcinoma, Carcinoma of the Large Intestine, Anal Cancer
Interventions
Observation
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 23, 2026, 12:21 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Catheter-directed Thrombolysis Compared to Anticoagulation Alone for Acute Primary Iliofemoral Deep Venous Thrombosis

NCT04411316
View directory record Official record
Conditions
Deep Venous Thrombosis, Post Thrombotic Syndrome
Interventions
Catheter directed thrombolysis plus anticoagulation, Anticoagulation
Combination Product · Drug
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Oct 23, 2026, 12:21 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

FUVID Study: Functional Characterization of Children With Chronic Venous Thromboembolic Disease

NCT04583878
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Blood draw (Visit 1), Blood draw (Visits 2 and 3)
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years to 21 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
14
States / cities
Little Rock, Arkansas • St. Petersburg, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 23, 2026, 12:21 AM EDT
Active, not recruiting Not applicable Interventional

The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study

NCT05489588
View directory record Official record
Conditions
Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
Interventions
GORE® VIAFORT Vascular Stent
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
24
States / cities
Stanford, California • Darien, Connecticut • New Haven, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 23, 2026, 12:21 AM EDT
Completed Phase 4 Interventional Results available

Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism

NCT04168203
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
Interventions
Apixaban 2.5 MG, Placebo oral tablet
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 23, 2026, 12:21 AM EDT
Withdrawn Not applicable Interventional

Novel Strategy to Encourage Early Removal of Central Venous Catheters

NCT04136561
View directory record Official record
Conditions
Vascular Access Complication, Central Line Complication, Central Line-Associated Infection, Superficial Vein Thrombosis, Deep Vein Thrombosis
Interventions
Midline catheter
Device
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 23, 2026, 12:21 AM EDT